JP Morgan Downgrades Boston Scientific to Neutral, Lowers Price Target
JP Morgan has downgraded Boston Scientific (BSX) from overweight to neutral. The decision follows an assessment that the medical device manufacturer is facing several new negative headwinds that are expected to weigh on the company's share price in the near term. In addition to the rating downgrade, the bank significantly reduced its price target for BSX from $56 to $46. This adjustment reflects a more cautious outlook on the stock's growth trajectory and potential market performance.
